Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies

The anti-spike T-cell and antibody responses to SARS-CoV-2 mRNA vaccines in patients with B-cell malignancies were examined in a real-world setting. A next-generation sequencing (NGS)–based molecular assay was used to assess SARS-CoV-2–specific T-cell responses. After the second dose, 58% (166/284)...

Descripción completa

Detalles Bibliográficos
Autores principales: Greenberger, Lee M., Saltzman, Larry A., Gruenbaum, Lore M., Xu, Jun, Reddy, Sneha T., Senefeld, Jonathon W., Johnson, Patrick W., Fields, Paul A., Sanders, Catherine, DeGennaro, Louis J., Nichols, Gwen L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Briefs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894565/
https://www.ncbi.nlm.nih.gov/pubmed/36074641
http://dx.doi.org/10.1158/2643-3230.BCD-22-0077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894565/
https://www.ncbi.nlm.nih.gov/pubmed/36074641
http://dx.doi.org/10.1158/2643-3230.BCD-22-0077

Ejemplares similares